Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis

Background: Anlotinib is a multi-target anti-angiogenic agent. This retrospective study aimed to evaluate the efficacy and safety of anlotinib alone or in combination with temozolomide for the treatment of recurrent high-grade glioma. Materials and Methods: The clinical data of patients with recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qunying, Guo, Chengcheng, Lin, Xiaoping, Luo, Lili, He, Zhenqiang, Lin, Fuhua, Zhang, Ji, Chen, Yinsheng, Jiang, Xiaobing, Ke, Chao, Mou, Yonggao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741259/
https://www.ncbi.nlm.nih.gov/pubmed/35002738
http://dx.doi.org/10.3389/fphar.2021.804942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741259/
https://www.ncbi.nlm.nih.gov/pubmed/35002738
http://dx.doi.org/10.3389/fphar.2021.804942

Ejemplares similares